Published in J Am Coll Cardiol on September 04, 2007
Drug-induced hematologic syndromes. Adv Hematol (2009) 1.11
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf (2013) 0.94
The role of plasmapheresis in critical illness. Crit Care Clin (2012) 0.88
The kidney in thrombotic thrombocytopenic purpura. Minerva Med (2007) 0.85
Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Tex Heart Inst J (2012) 0.82
Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2011) 0.79
Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature. J Res Med Sci (2011) 0.77
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. Vasc Health Risk Manag (2010) 0.77
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies. Rambam Maimonides Med J (2014) 0.76
Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection. J Neurol Surg Rep (2015) 0.75
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000) 5.43
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med (1998) 5.30
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem (2001) 3.02
Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A (2002) 2.23
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost (1994) 2.05
Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med (1998) 1.98
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost (1999) 1.69
Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med (2000) 1.48
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion (2006) 1.28
Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood (2003) 1.10
Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost (2004) 1.08
Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion (2004) 1.03
Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality. Cleve Clin J Med (2003) 1.01
Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood (2002) 1.00
Predicting in-hospital mortality of patients with AIDS-related Pneumocystis carinii pneumonia: an example of hierarchically optimal classification tree analysis. Stat Med (1997) 0.95
Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet (1998) 0.90
TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation (2002) 0.89
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol (2004) 0.88
Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost (2005) 0.86
Clopidogrel and thrombotic thrombocytopenic purpura. Lancet (2000) 0.84
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report. J Invasive Cardiol (2006) 0.84
Editorial comment--an approach to the estimation of the risk of TTP during clopidogrel therapy. Stroke (2004) 0.80
Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol (2004) 0.77
Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med (2000) 0.77
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
The prognostic value of a nomogram for exercise capacity in women. N Engl J Med (2005) 5.03
Amiodarone versus sotalol for atrial fibrillation. N Engl J Med (2005) 5.01
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation (2003) 4.19
The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med (2004) 3.96
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher (2010) 3.47
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol (2005) 3.38
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol (2006) 2.92
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Clinical predictors of bioterrorism-related inhalational anthrax. Lancet (2004) 2.79
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke (2008) 2.68
Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity (2012) 2.54
Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2011) 2.53
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med (2003) 2.49
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A (2002) 2.23
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol (2009) 2.16
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem (2003) 2.12
Visual hallucinations in an elderly woman: a presentation of Charles Bonnet syndrome? J Am Geriatr Soc (2006) 2.10
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation (2011) 2.08
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A (2006) 2.07
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol (2006) 2.06
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood (2003) 2.06
Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood (2008) 2.04
Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care (2007) 2.04
Reliability and validity of scores on The Emergency Severity Index version 3. Acad Emerg Med (2004) 2.03
Cefuroxime-induced immune hemolysis. J Pediatr (2003) 2.02
Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell (2012) 1.99
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. MMWR Surveill Summ (2009) 1.98
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med (2008) 1.97
Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura. J Obstet Gynaecol Res (2012) 1.96
Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 1.94
Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening. J Clin Oncol (2007) 1.91
Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2010) 1.88
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Localization of ADAMTS13 to the stellate cells of human liver. Blood (2005) 1.85
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood (2012) 1.83
Are electronic health records ready for genomic medicine? Genet Med (2009) 1.82
Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A (2008) 1.81
Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg (2015) 1.80
A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health (2010) 1.80
Impact of computerized prescriber order entry on the incidence of adverse drug events in pediatric inpatients. Pediatrics (2007) 1.79
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood (2008) 1.74
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Pathophysiology of contrast-induced nephropathy. Am J Cardiol (2006) 1.73
The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem (2005) 1.73
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73